Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for executive function in children with ADHD and sleep problems
IRCT20230524058282N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) and sleep disorder comparing Melatonin + methylphenidate with Placebo + methylphenidate (2 arms). Primary endpoints: Behavioral Rating Inventory of Executive Function subscales, Clinical Global Impression score and 1 more. Started Jun 2023; status: completed.
02
Drugs
melatonin
03
Conditions
attention deficit hyperactivity disorder (ADHD)sleep disorder
Beyond the preview
Go deeper on IRCT20230524058282N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230524058282N1.